Researchers solve science behind scalp cooling and the reasons for hair loss in cancer treatment

March 25, 2015

HAIR loss is one of the most distressing side-effects of cancer treatment and can even deter some patients from undergoing life-saving chemotherapy. But researchers at the University of Huddersfield are establishing the scientific basis for a rapidly-advancing scalp cooling technology that can ensure hair retention in a vast number of cases.

There is also an added benefit that the increased positivity of patients who retain their hair can help to boost their immune systems and therefore aid recovery.

Experienced cancer researcher Dr Nikolaos Georgopoulos heads the project and the other key figure is Omar Hussain. With an academic background in the pharmacology of cancer treatment, he has been working closely with the Huddersfield firm Paxman Coolers Ltd, an innovator in the field of scalp cooling and which is now the world's leading supplier of hair-loss prevention systems. Its scalp coolers have been used by more than 100,000 patients in 32 countries.

Omar has recently completed his two-year position as the associate in a UK government-backed Knowledge Transfer Partnership (KTP) formed between Paxman and the University of Huddersfield. Now he has embarked on a programme of doctoral research supervised by Dr Georgopoulos and fully-funded by Paxman.

The PhD project will build on the findings of the research team, who have conducted laboratory experiments which provide scientific backing for clinical evidence that scalp cooling can eliminate hair loss during chemotherapy in at least 50 per cent of cases.

The effectiveness of cooling

Progress has also been made in establishing why cooling works and the researchers have also explored its effectiveness and its limitations when different combinations of drugs are used during chemotherapy. Dr Georgopoulos, Omar Hussain and their collaborators are the first to have published scientific papers which demonstrate that cooling works. They include an article in the journal Toxicology in Vitro.

The two Huddersfield scientists have also attended the recent St Gallen International Breast Cancer Conference, held in Vienna, where they gave two poster presentations on aspects of the scalp cooling research.

Dr Georgopoulos said that there was a range of explanations for the effectiveness of cooling. For example, the lowered temperature of the scalp could result in greatly reduced blood flow to the area, so that less of the drug finds its way to the hair follicles. It is also possible that cooling reduces the level of drug uptake in the region of the hair cells, or that the same effect is produced by a lowering of the metabolism.

Omar's PhD research will lead to a deeper understanding of the science behind cooling, focussing on the issues of drug uptake and drug release.

Happier patients have stronger immune systems

The University of Huddersfield researchers and the Paxman firm are aware that the benefits of scalp cooling technology can extend beyond the issue of hair loss.

Figures have shown that eight per cent of patients refuse chemotherapy because they fear losing their hair, said Omar Hussain. "So to have our research out there is a reassurance to them," he added.

Clinicians tend to regard hair loss as "collateral damage" said Dr Georgopoulos. "What they care about, of course, is saving lives. But we know the difference that keeping hair makes to patients and there is evidence that happier patients have stronger immune systems."

"Mood relates to hormonal release and that can affect the function of the immune system. Positivity can have an effect - there are scientific papers which suggest that it affects the efficacy of the treatment.

"So if you look in a mirror and feel good about yourself because you have a full head of hair, that is a big psychological boost that can help people through their treatment."

The researchers and Paxman now hope that scalp cooling will be embedded as a routine part of chemotherapy and that it will be an established element of nurse training.

The managing director of Paxman is Richard Paxman, who commented: "We are delighted with the results of the University of Huddersfield research and are extremely excited that it is being presented at this year's International Breast Cancer Conference. Every day we hear personal stories from patients and their families about the positive results of scalp cooling so it is great to see clinical evidence to back this up."
-end-


University of Huddersfield

Related Chemotherapy Articles from Brightsurf:

Chemotherapy is used to treat less than 25% of people with localized sarcoma
UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone.

Starved cancer cells became more sensitive to chemotherapy
By preventing sugar uptake, researchers succeeded in increasing the cancer cells' sensitivity to chemotherapeutic treatment.

Vitamin D could help mitigate chemotherapy side effects
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.

Less chemotherapy may have more benefit in rectal cancer
GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose.

Male fertility after chemotherapy: New questions raised
Professor Delb├Ęs, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma.

'Combo' nanoplatforms for chemotherapy
In a paper to be published in the forthcoming issue in NANO, researchers from Harbin Institute of Technology, China have systematically discussed the recent progresses, current challenges and future perspectives of smart graphene-based nanoplatforms for synergistic tumor therapy and bio-imaging.

Nanotechnology improves chemotherapy delivery
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.

Novel anti-cancer nanomedicine for efficient chemotherapy
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.

Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.

A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.

Read More: Chemotherapy News and Chemotherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.